在前期已建立的异常黑胆质载体动物模型的基础上,采用聚集态Aβ1-40 双海马定向注射制备证病结合的异常黑胆质型阿尔茨海默病(AD)模型,并以Morris 水迷宫及跳台实验验证证病结合模型的行为学改变特点。结果表明,各组大鼠饮食、水量及体重变化:单纯(AD)组、异常黑胆质证组饮食、水量较正常对照组增加(P<0.05);证病结合的异常黑胆质型AD 模型组饮食、水量较异常黑胆质组减少(P<0.01);单纯AD 组、异常黑胆质证组、证病结合组体重较正常对照组均减轻(P<0.01)。各组大鼠Morris 水迷宫空间探索试验经过有效区域次数:与正常对照组比较,单纯AD 组、异常黑胆质证组、证病结合组经过有效区域次数均减少(P<0.01);与单纯AD 组相比,证病结合组经过有效区域次数明显减少(P<0.05)。各组大鼠跳台测试:与空白对照组比较,单纯AD 组、异常黑胆质证组和证病结合组反应期延长,潜伏期缩短,错误次数增多,学习记忆成绩明显降低(P<0.01);证病结合组与单纯痴呆组相比略低,但无统计学差异(P>0.05)。由此得出,在异常黑胆质载体大鼠模型的基础上,采用聚集态Aβ1-40 双海马定向注射制备证病结合的异常黑胆质型AD 模型,不仅动物体表特征的变化符合维医体液证候改变特点,通过行为学验证后学习记忆改变特点又符合西医疾病的特点。
This paper developed an Alzheimer's disease rat model carrying abnormal Savda syndrome and studied its behavioral changes. First of all, an abnormal Savda syndrome rat model was developed by using the classical method then β-Amyloid 1-40 was injected into hippocampus to establish Alzheimer's disease in these rats. After observing the biological characteristics and testing behavioral changes with Morris water maze test and step down test, the abilities of learning and memorizing of different model groups were compared. Compared with the normal group, the daily food and water intake was increased in the abnormal Savda syndrome group and the AD group (P<0.01), the body weigh was decreased in the abnormal Savda syndrome group, the AD group and the AD carrying abnormal Savda syndrome group (P<0.01). The numbers of crossing the effective area were reduced in the abnormal Savda syndrome group, the AD group and the AD carrying abnormal Savda syndrome group (P<0.01) with respect to the normal group. The number of crossing the effective area was smaller in the AD carrying abnormal Savda syndrome group (P<0.05) than that in the AD group. The learning and memory scores were significantly lower in the abnormal savda syndrome group, the AD group and the AD carrying abnormal Savda syndrome group (P<0.01) than those in the normal group. Compared with the AD group, the learning and memory scores slightly lowered in the AD carrying abnormal Savda syndrome group without any significant statistical difference(P > 0.05). In this research, the Alzheimer's disease carrying abnormal Savda syndrome rat model was developed successfully.
[1] Herholz K. Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease[J]. Expert Review of Neurotherapeutics, 2010, 10 (11): 1667-1673.
[2] 易沙克江·马合穆德. 中国医学百科全书维吾尔医学分卷[M]. 乌鲁木齐: 新疆科技卫生出版社, 1995, 221-224. Mahmud Ishakjan. Chinese medical encyclopedia Uighur medicine volume[M]. Xinjiang: Health Technology Press, 1995, 221-224.
[3] 阿衣努尔·买提斯迪克, 吾尔古力·阿卜杜来海提. 维药异常黑胆质成熟剂对异常黑胆质载体大鼠动物模型血液流变学指标的影响[J]. 科技导报, 2011, 29(27): 31-35. Maitisidike Ayinuer, Abudulaihaiti Wuerguli. Hemorheological effect of abnormal savda munziq, as a traditional Uighur medicine, on the abnormal savda rat model[J]. Science & Technology Review, 2011, 29 (27): 31-35.
[4] 玉苏甫·吐尔逊, 斯坎德尔·白克力. 异常黑胆质性肝癌病证模型肝硬化期的肝脏形态学研究[J]. 科技导报, 2010, 28(24): 82-88. Tursun Yusupjan, Bakri Iskandar. Morphological study on hepatic tissue in hepatocirrhosis phase of hepatocarcinoma carrying abnormal savda model[J]. Science & Technology Review, 2010, 28(24): 82-88.
[5] 阿布力孜·阿卜杜扎依尔, 哈木拉提·吾甫尔. 异常黑胆质成熟剂对异常黑胆质性癌病证模型肝硬化期的肝脏形态学的影响[J]. 科技导报, 2011, 29(28): 68-73. Abduzayir Abliz, Upur Halmurat. Effect of abnormal savda munziq on morphological structure of hepatic tissue in hepatocirrhosis phase of hepatocarcinoma carrying abnormal savda model[J]. Science & Technology Review, 2011, 29(28): 68-73.
[6] 张有辉, 哈木拉提·吾甫尔, 玉苏甫·吐尔逊, 等. 异常黑胆质证载体大鼠模型的建立及其免疫、内分泌紊乱状态的研究[J]. 新疆医科大学学报, 2010, 33(6): 596-598. Zhang Youhui, Upur Halmurat, Tursun Yusup, et al. Establishment of abnormal savda syndrome rat model and study on its disordered immune-endocrine network[J]. Journal of Xinjiang Medical University, 2010, 33(6): 596-598.
[7] Paxinos G, Watson C. The rat brain in stereotaxic coordinates[M]. London: Academic Press, 1986.
[8] Morris R G M. Spatial localization does not require the presence of local cues[J]. Learning and Motivation, 1981, 12(2): 239-260.
[9] 李静, 周东华, 王延红. 海马注射β -淀粉样蛋白建立阿尔茨海默病大鼠模型的实验研究[J]. 中国临床神经科学, 2008, 16(5): 467-470. Li Jing, Zhou Donghua, Wang Yanhong. The study on establishing AD rat model by intrahippocampal injection ofβ-amyloid[J]. Chinese Journal of Clinical Neuroscience, 2008, 16(5): 467-470.
[10] 张均田, 张庆柱. 神经药理研究技术与方法[M]. 北京: 人民卫生出版社, 2005, 297-299. Zhang Juntian, Zhang Qingzhu. Neuropharmacology research techniques and methods[M]. Beijing: People's Health Publishing House, 2005: 297-299.
[11] 木塔力甫·艾力阿吉. 维吾尔医精神病学[M]. 乌鲁木齐: 新疆人民卫生出版社, 2004, 87-89. AiliAji Mutalip. Psychiatry of Uygur medicine[M]. Urumqi: Xinjiang People's Health Publishing House, 2004, 87-89.
[12] 阿布里米提·玉素甫阿吉. 维吾尔医学基础理论[M]. 乌鲁木齐: 新疆人民卫生出版社, 1988: 189-192. YsupAji Abimit. Basic theory of Uygur medicine[M]. Urumqi: Xinjiang People's Health Publishing House, 1988: 189-192.
[13] Jeon S, Bose S, Hur J, et al. A modified formulation of Chinese traditional medicine improves memory impairment and reduces Aβ level in the Tg- APPswe/PS1dE9 mouse model of Alzheimer's disease[J]. Journal of Ethnopharmacology, 2011, 137(1): 783-789.
[14] 张有辉, 玉苏甫·吐尔逊, 哈木拉提·吾甫尔, 等. 异常黑胆质型肝癌病证模型肝硬化期内分泌—免疫紊乱的研究[J]. 科技导报, 2010, 28 (11): 39-41. Zhang Youhui, Tursun Yusupjan, Upur Halmurat, et al. The study on the endocrine- immune disorder of abnormal Savda cirrhotic liver cancer syndromes model[J]. Science & Technology Review, 2010, 28 (11): 39-41.
[15] 哈木拉提·吾甫尔, 阿依努尔·买提斯迪克, 努尔买买提·艾买提, 等. 异常黑胆质证载体动物模型的建立及其自然恢复反证[J]. 新疆医科大学学报, 2006, 29(10): 910-914. Upur Halmurat, Matsidik Aynur, Amat Nurmammat, et al. The establishment and evaluation of abnormal savda syndrome animal model[J]. Journal of Xinjiang Medical University, 2006, 29(10): 910- 914.
[16] Amat N, Upur H, Ablimit A. Immunomodulatory effects of abnormal savda munsiq, a traditional Uighur medicine, on the combined stress mice[J]. Journal of Ethnopharmacology, 2009, 122(1): 42-47.
[17] Salloway S, Mintzer J, Weiner M F, et al. Disease-modifying therapies in Alzheimer's disease[J]. Alzheimers Dement, 2008, 4(2): 65-79.
[18] Bennett S, Grant M M, and Aldred S. Oxidative stress in vascular dementia and Alzheimer's disease:a commonpathology[J]. Journal of Alzheimer's Disease, 2009, 17(2): 245-257.